Darleukin/fibromun

N/A

Report date: 2026/02/24 20:00:16

Base Information

Drug NameDarleukin/fibromun
Drug Alias NameL19-IL2 + L19-TNFDarleukin/fibromun - PhilogenFibromun/L19-IL2 fusion proteinL19IL2-L19TNFBifikafusp alfa/Onfekafusp alfa +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTumor necrosis factor receptor agonistsFibronectin inhibitorsInterleukin-2 stimulants
TargetsInterleukin-2Tumor necrosis factor receptorFibronectin
Therapy Area/IndicationsCarcinoma, Squamous CellCarcinoma, Basal CellMelanoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandItaly +[7] 
CombinationsYes Onfekafusp alfaBifikafusp alfa
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPhilogen Spa
China Registration ClassN/A

Develop Information

Active CompaniesSun Pharmaceutical Industries LtdPhilogen Spa
Inactive CompaniesN/A
Active IndicationsCarcinoma, Squamous CellCarcinoma, Basal CellMelanoma +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A